| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
orexin type 2 receptor[1]
Suntinorexton targets the orexin type 2 receptor (OX2R) as a selective and orally active agonist. It has an EC50 of 2.5 nM for OX2R. Orexin receptors are involved in the regulation of wakefulness, sleep-wake transitions, and appetite. By activating OX2R, Suntinorexton promotes wake-promoting signaling pathways in the central nervous system. Its oral activity and high potency make it a valuable tool for studying the specific roles of OX2R in sleep-wake regulation and for developing treatments for sleep disorders such as narcolepsy. |
|---|---|
| ln Vitro |
In vitro studies demonstrate that Suntinorexton (TAK-861) is an orally active and selective OX2R agonist with an EC50 of 2.5 nM. It activates OX2R with high potency and selectivity, promoting wake-promoting signaling pathways. The compound's oral activity and high potency make it a valuable tool for studying orexin receptor pharmacology and for developing small-molecule treatments for sleep disorders. Detailed in vitro characterization data, including receptor binding and functional assays, are available in the primary literature.
|
| ln Vivo |
In vivo studies of Suntinorexton have demonstrated its efficacy in ameliorating narcolepsy-like phenotypes. As an orally active OX2R agonist, it promotes wake-promoting signaling pathways in the central nervous system. Specific in vivo efficacy data, including effects on sleep-wake parameters and narcolepsy symptoms, are available in the primary literature. The compound's oral bioavailability supports its use in in vivo studies. Further research is ongoing to characterize its full therapeutic potential for narcolepsy and other sleep disorders.
|
| Enzyme Assay |
For OX2R binding assays, membrane preparations from cells expressing recombinant OX2R are incubated with radiolabeled ligands and varying concentrations of Suntinorexton. Non-specific binding is determined using excess unlabeled reference compounds. Following incubation at appropriate temperature (typically 25°C for 60-90 minutes), bound and free radioligands are separated by rapid filtration through glass fiber filters. Filters are washed and radioactivity counted by liquid scintillation. IC50 or Ki values are calculated from competition curves. For functional assays, receptor activation is measured by calcium flux or IP3 accumulation assays.
|
| Cell Assay |
For in vitro cellular assays, cell lines expressing OX2R (e.g., CHO or HEK293 cells) are cultured in appropriate media under standard conditions (37°C, 5% CO2). Suntinorexton is dissolved in DMSO and diluted in culture medium to desired concentrations. Cells are treated with compound for specified durations. Receptor activation is assessed by measuring intracellular calcium flux using fluorescent indicators or by measuring downstream signaling pathways. Cell viability and cytotoxicity can be assessed using standard assays. Each concentration is tested in replicate wells with vehicle controls and positive controls (e.g., orexin-A).
|
| Animal Protocol |
For in vivo animal studies, Suntinorexton is typically administered orally (by gavage) due to its oral activity. In narcolepsy models, animals are treated with compound and sleep-wake parameters are monitored using EEG/EMG recordings. Narcolepsy-like phenotypes, including cataplexy and sleep fragmentation, are assessed. For pharmacokinetic studies, blood and brain tissue samples are collected at predetermined time points post-administration, and drug concentrations are quantified by LC-MS/MS. All procedures must follow institutional animal care and use committee guidelines.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Suntinorexton indicate it is orally active. The compound has a molecular weight of 466.54 and formula C23H28F2N2O4S. CAS number: 2274802-89-8. Storage: typically at -20°C for powder; in solvent at -80°C. Solubility: soluble in DMSO and other organic solvents. As a small-molecule OX2R agonist, it is expected to have favorable oral bioavailability. Specific pharmacokinetic parameters such as half-life, clearance, and bioavailability are reported in the primary literature.
|
| Toxicity/Toxicokinetics |
According to available safety information, Suntinorexton is intended for research purposes only and is not for human therapeutic use. Standard laboratory safety precautions should be followed when handling this compound, including the use of appropriate personal protective equipment (gloves, lab coat, safety goggles). The compound should be handled in a well-ventilated area. Avoid dust formation and inhalation. In case of skin contact, wash with plenty of soap and water. In case of eye contact, rinse cautiously with water for several minutes. No clinical toxicity data are available.
|
| References | |
| Additional Infomation |
Suntinorexton (TAK-861) is an orally active and selective OX2R agonist with an EC50 of 2.5 nM. It is a heterocyclic compound that ameliorates narcolepsy-like phenotypes. It has a molecular weight of 466.54 and formula C23H28F2N2O4S. It is for research use only with no regulatory approvals reported.
|
| Molecular Formula |
C23H28F2N2O4S
|
|---|---|
| Molecular Weight |
466.54
|
| Exact Mass |
466.173
|
| CAS # |
2274802-89-8
|
| Related CAS # |
(R,R)-Suntinorexton
|
| PubChem CID |
137460941
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.2
|
| tPSA |
95.1
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
32
|
| Complexity |
758
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C(S(N[C@H]1CCN(C(=O)C(O)(C)C)[C@H]1CC1C=CC=C(C2=CC=CC(F)=C2)C=1F)(=O)=O)C
|
| InChi Key |
MQDUVMBBJZLFHF-PMACEKPBSA-N
|
| InChi Code |
InChI=1S/C23H28F2N2O4S/c1-4-32(30,31)26-19-11-12-27(22(28)23(2,3)29)20(19)14-16-8-6-10-18(21(16)25)15-7-5-9-17(24)13-15/h5-10,13,19-20,26,29H,4,11-12,14H2,1-3H3/t19-,20-/m0/s1
|
| Chemical Name |
N-[(2S,3S)-2-[[2-fluoro-3-(3-fluorophenyl)phenyl]methyl]-1-(2-hydroxy-2-methylpropanoyl)pyrrolidin-3-yl]ethanesulfonamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~200 mg/mL (~428.7 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 5 mg/mL (10.72 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (50.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 5 mg/mL (10.72 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (50.0 mg/mL) to 900 μL of corn oil and mix well.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1434 mL | 10.7172 mL | 21.4344 mL | |
| 5 mM | 0.4287 mL | 2.1434 mL | 4.2869 mL | |
| 10 mM | 0.2143 mL | 1.0717 mL | 2.1434 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.